MRNA vs. BNTX

In the year-to-date period, MRNA achieves a -36.84% return, which is significantly lower than BNTX's -13.40% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Moderna, Inc. (MRNA) and BioNTech SE (BNTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current MRNA Sharpe Ratio is -1.23, which is lower than the BNTX Sharpe Ratio of -0.01. The chart below compares the historical Sharpe Ratios of MRNA and BNTX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither MRNA nor BNTX has paid dividends to shareholders.

The maximum MRNA drawdown since its inception was -95.12%, which is greater than BNTX's maximum drawdown of -82.48%. Use the drawdown chart below to compare losses from any high point for MRNA and BNTX.

Moderna, Inc. (MRNA) and BioNTech SE (BNTX) have volatilities of 22.15% and 21.23%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Moderna, Inc. and BioNTech SE. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.